Finanzas de Danaher Corp (DHR)DHRDanaher Corp

Danaher Corporation (DHR) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostics, accounting for 44.0% of total sales, equivalent to $2.88B. Other significant revenue streams include Life Sciences and Biotechnology. Understanding this composition is critical for investors evaluating how DHR navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Danaher Corporation maintains a gross margin of 59.34%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.79%, while the net margin is 18.42%. These profitability ratios, combined with a Return on Equity (ROE) of 8.19%, provide a clear picture of how effectively DHR converts its operational activities into shareholder value.

In the context of the broader market, DHR competes directly with industry leaders such as ISRG and ABT. With a market capitalization of $164.53B, it holds a significant position in the sector. When comparing efficiency, DHR's gross margin of 59.34% stands against ISRG's 67.45% and ABT's 50.77%. Such benchmarking helps identify whether Danaher Corporation is trading at a premium or discount relative to its financial performance.

Danaher has shown consistent revenue growth, with Q3 2026 revenue at $6.55 billion and a gross margin of 59.34%. The company also raised its full-year EPS guidance to between $8.57 and $8.62, reflecting confidence in future performance.